See more : PLAID,Inc. (PLDIF) Income Statement Analysis – Financial Results
Complete financial analysis of Defence Therapeutics Inc. (DTCFF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Defence Therapeutics Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- ABV Consulting, Inc. (ABVN) Income Statement Analysis – Financial Results
- PJSC LSR Group (LSRG.ME) Income Statement Analysis – Financial Results
- SanFeng Intelligent Equipment Group Co., Ltd. (300276.SZ) Income Statement Analysis – Financial Results
- Mitsubishi Pencil Co., Ltd. (7976.T) Income Statement Analysis – Financial Results
- London Stock Exchange Group plc (LNSTY) Income Statement Analysis – Financial Results
Defence Therapeutics Inc. (DTCFF)
About Defence Therapeutics Inc.
Defence Therapeutics Inc., a biotechnology company, engages in the research and development of biological/biosimilar therapeutic drugs for cancer and infectious diseases. Its proprietary platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. The company focuses on developing dendritic cell cancer vaccines; protein-based vaccine formulation against COVID and infectious diseases; and antibody drug conjugates (ADC) products targeting various cancers. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. Defence Therapeutics Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -13.82K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 3.86M | 3.58M | 3.76M | 1.16M | 433.45K | 0.00 |
| General & Administrative | 1.25M | 641.39K | 1.04M | 1.36M | 239.73K | 41.95K |
| Selling & Marketing | 1.71M | 1.96M | 2.52M | 341.10K | 0.00 | 41.90K |
| SG&A | 8.79M | 2.90M | 3.56M | 1.70M | 239.73K | 41.95K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Cost & Expenses | 12.66M | 6.48M | 7.32M | 2.86M | 673.18K | 41.95K |
| Interest Income | 0.00 | 6.81K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 262.93K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 70.94K | 13.82K | 7.27M | 2.83M | 673.18K | 41.95K |
| EBITDA | -12.68M | -6.48M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -12.66M | -6.48M | -7.30M | -2.86M | -673.18K | -41.95K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -537.24K | -387.15K | -70.18K | 0.00 | 0.00 | 40.00K |
| Income Before Tax | -13.19M | -6.87M | -7.34M | -2.86M | -673.18K | -1.95K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 105.00K | 16.59K | -1.16M | -434.13K | -41.95 |
| Net Income | -13.19M | -6.76M | -7.34M | -2.86M | -673.18K | -1.95K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| EPS Diluted | -0.30 | -0.17 | -0.20 | -0.11 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
| Weighted Avg Shares Out (Dil) | 44.63M | 39.66M | 36.08M | 26.60M | 34.80M | 34.80M |
Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine
Vancouver, British Columbia--(Newsfile Corp. - May 1, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful...
Defence's AccuTOX Anti-Cancer ARM-002 Vaccine Exhibits Potent Antigen Presentation
Vancouver, British Columbia--(Newsfile Corp. - April 23, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that its...
Defence Therapeutics Signs with German Based FMS Consult GmbH for Financing Strategy to Support Defence Pipeline Growth
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce that FMS...
Defence Therapeutics Announces Warrant Terms Amendment
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces an amendment to the...
Defence's Successful Results on Its AccuTOX Anti-Cancer ARM Vaccine Creates a Potent Second-Generation Anti-Cancer ARM-002 Vaccine
Vancouver, British Columbia--(Newsfile Corp. - March 26, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biotechnology company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the successful...
Defence Completes 2nd Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - March 22, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC), ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the...
Defence Therapeutics Awarded Broad U.S. Patent Covering Its Pioneering Cancer-Killing AccuTOX(R) Technology
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology therapeutics and drug delivery technologies, is pleased to announce the granting...
Defence Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update
Vancouver, British Columbia--(Newsfile Corp. - February 29, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, is pleased to announce the...
Defence Therapeutics Completes 1st Tranche of Financing
Vancouver, British Columbia--(Newsfile Corp. - January 30, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology, announces the closing of the 1st...
Defence Financing
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), one of the leading Canadian biotechnology companies working in the field of immune-oncology announces, further to its news release...
Source: https://incomestatements.info
Category: Stock Reports